Replies to post #251394 on Biotech Values

[DewDiligence]

This is the writeup on GLP-1 for Parkinson’s:

https://www.statnews.com/2024/04/03/parkinsons-glp1-diabetes-obesity-study/

[zipjet]

The GLP-1 agonists, originally developed to treat type 2 diabetes mellitus, have shown potential in slowing the loss of motor function in Parkinson's disease (PD) patients. Several studies and clinical trials have investigated the neuroprotective effects of these drugs, which can activate the GLP-1 receptor in the brain, potentially influencing neuronal metabolism, repair, and synaptic efficacy.
A recent Phase 2 trial reported that patients with early Parkinson's disease taking the GLP-1 diabetes drug lixisenatide experienced no worsening of their symptoms, in contrast to patients on placebo
5
. Although the difference in motor function between the two groups was small, the results were seen as a positive signal, suggesting that GLP-1 agonists might offer a new approach to treating this slow-moving, debilitating disorder. The trial was conducted over one year, and the question remains whether longer-term use of the drug could result in additional benefits
5
.
Previous studies have also supported the use of GLP-1 agonists in Parkinson's disease. For instance, a study published in 2017 found that Parkinson's patients treated with exenatide, another GLP-1 drug, showed improved motor features, and these improvements persisted 12 months after stopping the drug
5
. This finding suggests that GLP-1 agonists may have disease-modifying effects rather than merely providing symptomatic relief.
The neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders such as PD are being explored due to their ability to reduce inflammation and protect neurons from dying
5
6
. The GLP-1 receptor is present in the brain, and its activation is thought to be anti-inflammatory by reducing microglial activation
7
. This could potentially prevent the steady loss of dopamine-producing neurons that characterizes Parkinson's disease.
While the evidence is promising, further research is needed to confirm the long-term effects of GLP-1 agonists on Parkinson's disease progression and to determine the best dosing strategies to control side effects
8
. Ongoing and future clinical trials will be crucial in establishing the efficacy and safety of GLP-1 receptor agonists as a treatment for Parkinson's disease.